Artera: Personalizing Treatment Decisions in Prostate Cancer and Beyond...
In this latest episode of Exploring Artificial Intelligence in Oncology, Fellows Forum member Dr. Waqas Haque sits down with [...]
Artera’s Multimodal Artificial Intelligence Named Among TIME’s 2024 Best...
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced th [...]
MMAI Score Prognostic for Overall Survival in Oligometastatic Castration-Sensitive...
Phuoc Tran and Tim Showalter join Zachary Klaassen to discuss two presentations examining the ArteraAI prostate test in..
AI’s Role in Predicting Cancer Treatment Outcomes
In this episode of the Target Cancer Podcast, Dr. Sanjay Juneja talks with Dr. Tim Showalter, CMO at Artera, about using AI t [...]
Investigating AWS and GitHub Actions Runners Network conflict
In modern DevOps workflows, continuous integration and deployment pipelines are critical for maintaining rapid development cy [...]
Prostate Cancer Risk Stratification in NRG Oncology Phase III...
Current clinical risk stratification methods for localized prostate cancer are suboptimal, leading to over- and undertreatmen [...]
Artera Receives California Lab License, Expanding Access to its...
Clinicians and patients in California can now access personalized, actionable insights to inform prostate cancer treatment de [...]
AI-Powered Prostate Cancer Risk Assessment Tool Validated for Low-risk...
Alicia Morgans interviews Andre Esteva about ArteraAI's expanded prostate cancer test, now validated for low-risk and active [...]